Novavax Sketch Plan for Expansion Approved
June 15, 2021
Shulman Rogers congratulates NOVAVAX, Inc. on its herculean accomplishments in the global fight against COVID-19. Novavax is 1 of 8 drug makers awarded funding under the Operation Warp Speed federal program in July 2020 to develop, test, manufacture and deliver a COVID-19 vaccine. Novavax has met the challenge on all fronts.
In less than a year, Novavax, with its team including Shulman Rogers, secured two sites in the City of Gaithersburg and obtained zoning approvals for a 180,000 square feet Global Headquarters and manufacturing facility delivering late summer at 700 Quince Orchard, and an additional 600,000+ square feet integrated campus next door at 14 Firstfield Road for expansion of its manufacturing and research and development capacity.
Shulman Rogers land use attorney, Nancy Regelin, assisted Novavax with site selection, acquisition and the zoning approvals, including its most recent approval on June 7, 2021 from the Mayor & Council of Gaithersburg for its 15-acre global headquarters campus, which is expected to bring over 1000 jobs to the City.
Commenting on the proposed campus expansion, Regelin said, “It has been especially gratifying to work on this particular development plan, knowing the impact Novavax will have in the global fight against COVID-19 and other world health challenges in the future.”
On June 14, 2021, Novavax reported the highly successful results of the Phase 3 clinical trials of its COVID-19 vaccine candidate. Novavax announced that it will file for emergency use authorization of its vaccine in the USA and throughout the world. Once authorized, Novavax will be the 3rd Operation Warp Speed vaccine developer to receive FDA emergency use authorization for its COVID-19 vaccine. The 700 Quince Orchard Headquarters building is designed to begin manufacturing the vaccine later this year to supplement manufacture of its vaccine which has already begun at partner facilities throughout the world.
Click HERE to read the full story about Novavax’s expansion from Bethesda Magazine.